Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather L Martin

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Plos One|February 8, 2014
High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markersHeather L Martin, Matthew Adams, Julie Higgins, et al.
New Biotechnology|February 24, 2018
Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancerHeather L Martin, Robert Bedford, Sophie J Heseltine, et al.
Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.
Neurobiology of Disease|February 28, 2016
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinMatteo Santoro, Walter Maetzler, Petros Stathakos, et al.
Scientific Reports|November 16, 2024
Generating and validating renewable affimer protein binding reagents targeting SH2 domainsSophie J Heseltine, Gregory J Billenness, Heather L Martin, et al.
Iscience|August 6, 2024
Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particlesSophie E Roberts, Heather L Martin, Danah Al-Qallaf, et al.
Cell Reports|September 30, 2023
Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibitionHeather L Martin, Amy L Turner, Julie Higgins, et al.
Nature Communications|July 1, 2021
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric siteKatarzyna Z Haza, Heather L Martin, Ajinkya Rao, et al.
Oncotarget|February 9, 2017
Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastasesPeter J Webster, Anna T Littlejohns, Hannah J Gaunt, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Plos One|February 8, 2014
High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markersHeather L Martin, Matthew Adams, Julie Higgins, et al.
New Biotechnology|February 24, 2018
Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancerHeather L Martin, Robert Bedford, Sophie J Heseltine, et al.
Brain : a Journal of Neurology|November 22, 2012
S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayKinnari Sathe, Walter Maetzler, Johannes D Lang, et al.
Neurobiology of Disease|February 28, 2016
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizinMatteo Santoro, Walter Maetzler, Petros Stathakos, et al.
Scientific Reports|November 16, 2024
Generating and validating renewable affimer protein binding reagents targeting SH2 domainsSophie J Heseltine, Gregory J Billenness, Heather L Martin, et al.
Iscience|August 6, 2024
Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particlesSophie E Roberts, Heather L Martin, Danah Al-Qallaf, et al.
Cell Reports|September 30, 2023
Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibitionHeather L Martin, Amy L Turner, Julie Higgins, et al.
Nature Communications|July 1, 2021
RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric siteKatarzyna Z Haza, Heather L Martin, Ajinkya Rao, et al.
Oncotarget|February 9, 2017
Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastasesPeter J Webster, Anna T Littlejohns, Hannah J Gaunt, et al.
Pageof 2